25 - 27 March | Boston, USA

Neuroimmunology Drug Development

Join us and leading neuroimmunology speakers, including Roche, Vigil Neuroscience, Merck, Lundbeck, Pipeline Therapeutics, and BMS, across 3 jam-packed conference days spanning discovery, preclinical, and translational development. To explore "Harnessing State-of-the-Art Microglial iPSCs, In Vivo Models & Neuroinflammatory Biomarkers to Accelerate Neurodegenerative Drugs into the Clinic".

Conference website

Neuroimmunology Drug Development

Join us and leading neuroimmunology speakers, including Roche, Vigil Neuroscience, Merck, Lundbeck, Pipeline Therapeutics, and BMS, across 3 jam-packed conference days spanning discovery, preclinical, and translational development. To explore "Harnessing State-of-the-Art Microglial iPSCs, In Vivo Models & Neuroinflammatory Biomarkers to Accelerate Neurodegenerative Drugs into the Clinic".

Conference website

We are sponsors at this event!

Come and visit our team at our booth and meet our team to discuss how bit.bio offers partnering opportunities that affords access to the most relevant parental human cell types and corresponding disease models. These models are physiologically relevant and highly characterised, offering predictive, in vitro, human cells for early drug discovery, phenotypic screening, and high-content imaging applications.

More details coming soon!

Arrange a meeting

Related pages

News Read our latest updates and press coverage
Blog Learn more about cells, our products, company and culture
About us Find out more about us and our people